17 Dec 2010 09:51
17 December 2010
OMEGA DIAGNOSTICS GROUP PLC
("OMEGA DIAGNOSTICS" OR THE "COMPANY")
Result of General Meeting
Omega Diagnostics, the AIM-listed medical diagnostics company, announces that at today's General Meeting of the Company all resolutions were duly passed. Shareholders have approved the acquisition of the business and certain assets of the IVD Business of Allergopharma Joachim Ganzer KG, a leading European allergy testing business, for consideration of €6.0 million together with a placing of 64,583,350 new ordinary shares at 12 pence per share to raise GBP7.75 million before expenses. The Acquisition constitutes a reverse acquisition under the AIM Rules for Companies. Accordingly, the Company has applied for re admission of the Enlarged Share Capital to trading on AIM. It is anticipated that 4,999,950 of the Placing Shares will be admitted to trading on 20 December 2010 and 59,583,400 of the Placing Shares will be admitted to trading on 21 December 2010 along with re admission of the existing ordinary share capital as required under the AIM Rules for Companies.
Defined terms used in this announcement shall have the same meaning as ascribed to them in the Company's announcement of 17 November 2010.
For further information please contact:
Omega Diagnostics Group plc | Tel: 01259 763 030 |
Andrew Shepherd, Chief Executive | |
Kieron Harbinson, Group Finance Director | www.omegadiagnostics.com |
Cenkos Securities plc | Tel: 020 7397 8900 |
Ian Soanes | |
Elizabeth Bowman | |
Walbrook PR Limited | Tel: 020 7933 8780 |
Fiona Henson | |
Helen Westaway | |
Paul Cornelius | Tel: 020 7933 8794 |